The study found that AR-FL and AR-V7 may serve as prognostic biomarkers for high tumor burden in mCRPC patients prior to treatment with Pluvicto, but none of these parameters correlated with response to PSMA treatment. The gene discussed is AR; the disease is neoplasm.